Bradley Carthon, MD, PhD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (170 ratings)

Role

Medical Oncology
Specialty

Bladder Cancer Kidney (Renal) Cancer Penile Cancer Prostate Cancer Testicular Cancer Uterine Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2011

Call 404-778-1900

Background

Bradley C. Carthon, MD, PhD, is an associate professor in Emory University School of Medicine's Department of Hematology and Medical Oncology. Dr. Carthon also serves as Section Chief of Hematology and Oncology at Emory University Hospital Midtown. He works with the genitourinary oncology team at Winship Cancer Institute in order to discover novel therapeutic targets and carry out clinical trials that utilize novel treatment combinations for our patients with prostate, bladder, and renal and other genitourinary malignancies.

Dr. Carthon previously served as Medical Director of Inpatient Medical Oncology at Winship Cancer Institute, Clifton Campus, during a period of notable growth in staffing and patient volume. He also previously served as Chair of Winship Cancer Institute's Health Disparities, Health Literacy and Minority Accrual Committee. He is a former participant in the Emory University School of Medicine Professional Leadership Enrichment and Development Program.

Dr. Carthon is a member of the Discovery and Developmental Therapeutics research program at Winship. He is also a member of the Annual Meeting Education Committee for American Society of Clinical Oncology.

Dr. Carthon earned his medical degree from Harvard Medical School in Boston, Massachusetts. He completed an internship and residency at Massachusetts General Hospital in Boston, Massachusetts. Dr. Carthon then went on to complete a fellowship at the University of Texas MD Anderson Cancer Center in Houston, Texas.

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Section Chief of Hematology and Oncology

Winship Cancer Institute at Emory Midtown

Education & Training

Education

Fellowship, Medical Oncology, 2011
Univ Texas M.D. Anderson Cancer Center
Residency, , 2008
Mass General Hospital
Internship, Internal Medicine, 2006
Mass General Hospital
Medical Education, , 2005
Harvard Medical School

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2011
Internal Medicine
American Board of Internal Medicine, 2008

View Current Clinical Trials


Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer Phase I Conditions Prostate Cancer Location Winship Cancer Institute

Title/Journal	Authors	Publication Date
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. Cancer	EJ Miller, TL Rose, BL Maughan, MI Milowsky, MA Bilen, BC Carthon, X Gao, S Rapisuwon, Q Zhao, M Yu, N Agarwal, MD Galsky	05/01/2024
Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study. Archives of pathology & laboratory medicine	S Bidot, J Yin, P Zhou, L Zhang, KK Deeb, G Smith, CE Hill, J Xiu, MA Bilen, KB Case, M Tinsley, B Carthon, LR Harik	03/01/2024
Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual. Frontiers in health services	JA Hoin, BC Carthon, SJ Brown, LM Durham, LC Garrot, SA Ghamande, AW Pippas, BM Rivers, CT Snyder, SGA Gabram-Mendola	01/01/2024
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Cancer	B Nazha, T Zhuang, S Wu, JT Brown, D Magee, BC Carthon, O Kucuk, C Nabhan, PC Barata, EI Heath, CJ Ryan, RR McKay, VA Master, MA Bilen	12/15/2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors. The oncologist	GE Sanda, JM Shabto, S Goyal, Y Liu, DJ Martini, B Nazha, JT Brown, LB Yantorni, G Anne Russler, S Caulfield, SS Joshi, VM Narayan, H Kissick, K Ogan, VA Master, BC Carthon, O Kucuk, MA Bilen	12/11/2023
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression. Cancers	A Hadadi, HB Krause, A Elliott, JT Brown, B Nazha, LR Harik, BC Carthon, B Miron, C Nabhan, PC Barata, M Saleh, Y Yang, RR McKay, MA Bilen	12/06/2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. Clinical genitourinary cancer	BC Carthon, SE Kim, DF McDermott, JP Dutcher, M Puligandla, J Manola, M Pins, MA Carducci, ER Plimack, LJ Appleman, GR MacVicar, M Kohli, TM Kuzel, RS DiPaola, NB Haas	10/01/2023
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	TZ Zhuang, D Ravindranathan, Y Liu, DJ Martini, JT Brown, B Nazha, G Russler, LB Yantorni, S Caulfield, BC Carthon, O Kucuk, VA Master, MA Bilen	03/17/2023
Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [⁶⁸Ga]Ga DOTATATE PET-CT. Cancers	MA Bilen, A Akintayo, Y Liu, O Abiodun-Ojo, O Kucuk, BC Carthon, DM Schuster, EE Parent	12/08/2022
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence. JAMA oncology	S Halabi, BC Carthon, WK Kelly	08/01/2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. Journal of immunotherapy and precision oncology	DJ Martini, TA Olsen, S Goyal, Y Liu, ST Evans, EE Hitron, GA Russler, L Yantorni, S Caulfield, JT Brown, JM Goldman, B Nazha, BC Carthon, WB Harris, O Kucuk, VA Master, MA Bilen	08/01/2022
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. Journal for immunotherapy of cancer	JW Carlisle, CS Jansen, MA Cardenas, E Sobierajska, AM Reyes, R Greenwald, L Del Balzo, N Prokhnevska, O Kucuk, BC Carthon, PC Mullane, A Osunkoya, D Baumgarten, F Hosseinzadeh, S Wilkinson, R Lake, AG Sowalsky, Y Liu, VA Master, MA Bilen, H Kissick	07/01/2022
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. Cancers	TZ Zhuang, K Case, TA Olsen, JT Brown, BC Carthon, O Kucuk, J Goldman, W Harris, MA Bilen, B Nazha	06/10/2022
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma. The oncologist	B Nazha, TZ Zhuang, HI Dada, LM Drusbosky, JT Brown, D Ravindranathan, BC Carthon, O Kucuk, J Goldman, VA Master, MA Bilen	06/08/2022
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Urologic oncology	A Hadadi, KE Smith, L Wan, JR Brown, G Russler, L Yantorni, S Caulfield, J Lafollette, M Moore, O Kucuk, B Carthon, B Nazha, Y Liu, MA Bilen	06/01/2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clinical cancer research : an official journal of the American Association for Cancer Research	F Meric-Bernstam, NM Tannir, O Iliopoulos, RJ Lee, ML Telli, AC Fan, A DeMichele, NB Haas, MR Patel, JJ Harding, MH Voss, TK Owonikoko, B Carthon, R Srinivasan, JC Bendell, Y Jenkins, SH Whiting, K Orford, MK Bennett, TM Bauer	04/14/2022
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer	H Emamekhoo, MR Olsen, BC Carthon, A Drakaki, IJ Percent, AM Molina, DC Cho, JC Bendell, LN Gordan, A Rezazadeh Kalebasty, DJ George, TE Hutson, ER Arrowsmith, J Zhang, J Zoco, JL Johansen, DK Leung, SS Tykodi	03/01/2022
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. Clinical genitourinary cancer	DJ Martini, ST Evans, Y Liu, JM Shabto, OE Uner, TA Olsen, JT Brown, GA Russler, L Yantorni, S Caulfield, JM Goldman, B Nazha, WB Harris, VA Master, O Kucuk, BC Carthon, MA Bilen	02/01/2022
A Contemporary Clinicopathologic Analysis of Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral, or Bladder Carcinoma. International journal of surgical pathology	F Chen, S Joshi, BC Carthon, AO Osunkoya	02/01/2022
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Frontiers in endocrinology	TA Olsen, TZ Zhuang, S Caulfield, DJ Martini, JT Brown, BC Carthon, O Kucuk, W Harris, MA Bilen, B Nazha	01/01/2022
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report. Frontiers in oncology	TZ Zhuang, L Harik, S Force, A Hadadi, MA Bilen, JT Brown, BC Carthon, J Goldman, O Kucuk, VA Master, B Nazha	01/01/2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. Journal for immunotherapy of cancer	PA Zucali, CC Lin, BC Carthon, TM Bauer, M Tucci, A Italiano, R Iacovelli, WC Su, C Massard, M Saleh, G Daniele, A Greystoke, M Gutierrez, S Pant, YC Shen, M Perrino, R Meng, G Abbadessa, H Lee, Y Dong, M Chiron, R Wang, L Loumagne, L Lépine, J de Bono	01/01/2022
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, JM Shabto, S Goyal, Y Liu, TA Olsen, ST Evans, BL Magod, D Ravindranathan, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, SS Joshi, HT Kissick, KE Ogan, WB Harris, O Kucuk, BC Carthon, VA Master, MA Bilen	12/01/2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. The oncologist	KER Smith, JT Brown, L Wan, Y Liu, G Russler, L Yantorni, S Caulfield, J Lafollette, M Moore, O Kucuk, B Carthon, B Nazha, MA Bilen	11/01/2021
Primary urothelial carcinoma of the ureter without concurrent renal pelvic or bladder carcinoma: A contemporary clinicopathologic analysis. Pathology, research and practice	CM Gutierrez, BC Carthon, S Joshi, AO Osunkoya	10/01/2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, S Goyal, Y Liu, ST Evans, TA Olsen, K Case, BL Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, WB Harris, HT Kissick, VA Master, O Kucuk, BC Carthon, MA Bilen	10/01/2021
Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. Clinical genitourinary cancer	KM Xu, Y Liu, TW Gillespie, AO Osunkoya, B Carthon, MA Bilen, CP Filson, K Ogan, PR Patel, JW Shelton, O Kucuk, S Joshi, AB Jani	08/01/2021
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Journal for immunotherapy of cancer	JT Brown, Y Liu, JM Shabto, D Martini, D Ravindranathan, EE Hitron, GA Russler, S Caulfield, L Yantorni, SS Joshi, H Kissick, K Ogan, B Nazha, BC Carthon, O Kucuk, WB Harris, VA Master, MA Bilen	07/01/2021
Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. The oncologist	B Carthon, HC Sibold, S Blee, R D Pentz	07/01/2021
¹⁸F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet (London, England)	AB Jani, E Schreibmann, S Goyal, R Halkar, B Hershatter, PJ Rossi, JW Shelton, PR Patel, KM Xu, M Goodman, VA Master, SS Joshi, O Kucuk, BC Carthon, MA Bilen, OA Abiodun-Ojo, AA Akintayo, VR Dhere, DM Schuster	05/22/2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	JT Brown, Y Liu, JM Shabto, DJ Martini, D Ravindranathan, EE Hitron, GA Russler, S Caulfield, LB Yantorni, SS Joshi, H Kissick, K Ogan, WB Harris, BC Carthon, O Kucuk, VA Master, MA Bilen	05/01/2021
Surgical Pathology Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy With Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder: A Contemporary Analysis. International journal of surgical pathology	J Kagan, M Alemozaffar, B Carthon, AO Osunkoya	04/01/2021
Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal? American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	FC Cackowski, B Mahal, EI Heath, B Carthon	03/01/2021
Exploratory study of ¹⁸F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. American journal of nuclear medicine and molecular imaging	AA Akintayo, MA Bilen, OA Abiodun-Ojo, O Kucuk, B Carthon, Z Chen, AB Jani, EE Parent, DM Schuster	01/01/2021
Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer treatment and research communications	DJ Martini, MR Kline, Y Liu, JM Shabto, BC Carthon, GA Russler, L Yantorni, EE Hitron, S Caulfield, JM Goldman, WB Harris, O Kucuk, VA Master, MA Bilen	01/01/2021
Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. Clinical and translational radiation oncology	JR Janopaul-Naylor, J Zhong, Y Liu, C Zhang, AO Osunkoya, SS Joshi, MA Bilen, B Carthon, O Kucuk, LM Hartsell, J Shelton, AB Jani	01/01/2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Frontiers in oncology	DJ Martini, TA Olsen, S Goyal, Y Liu, ST Evans, B Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, HT Kissick, WB Harris, O Kucuk, BC Carthon, VA Master, MA Bilen	01/01/2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. Frontiers in oncology	TA Olsen, DJ Martini, S Goyal, Y Liu, ST Evans, B Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, WB Harris, O Kucuk, BC Carthon, VA Master, B Nazha, MA Bilen	01/01/2021
Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (¹⁸F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer. International journal of radiation oncology, biology, physics	A Jani, E Schreibmann, S Goyal, H Raghuveer, B Hershatter, PJ Rossi, JW Shelton, PR Patel, KM Xu, M Goodman, V Master, SS Joshi, O Kucuk, B Carthon, MA Bilen, S Cooper, B Fielder, O Abiodun-Ojo, VR Dhere, DM Schuster	12/01/2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British journal of cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	10/01/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, C Wu, WB Harris, M Akce, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri	06/01/2020
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Cancer medicine	JM Shabto, DJ Martini, Y Liu, D Ravindranathan, J Brown, EE Hitron, GA Russler, S Caulfield, H Kissick, M Alemozaffar, K Ogan, WB Harris, VA Master, O Kucuk, BC Carthon, MA Bilen	04/01/2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. The oncologist	MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, A Speak, C Lewis, H Collins, HT Kissick, BC Carthon, M Akce, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master	03/01/2020
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, Y Liu, JM Shabto, BC Carthon, EE Hitron, GA Russler, S Caulfield, HT Kissick, WB Harris, O Kucuk, VA Master, MA Bilen	03/01/2020
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer	DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master, MA Bilen	02/01/2020
Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. Frontiers in oncology	MA Bilen, JF Jiang, CS Jansen, JT Brown, LR Harik, A Sekhar, H Kissick, SK Maithel, O Kucuk, B Carthon, VA Master	01/01/2020
Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study. Therapeutic advances in medical oncology	AI Abousaud, MS Barbee, CC Davis, SE Caulfield, Z Wang, A Boykin, BC Carthon, K Gogineni	01/01/2020
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational new drugs	DJ Martini, Y Liu, JM Shabto, C Lewis, MR Kline, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, VA Master, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, MA Bilen	12/01/2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC cancer	MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, H Kissick, BC Carthon, WL Shaib, OB Alese, CE Steuer, C Wu, DH Lawson, R Kudchadkar, VA Master, B El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey	08/29/2019
Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. American journal of clinical oncology	J Zhong, J Switchenko, NK Jegadeesh, RJ Cassidy, TW Gillespie, V Master, P Nieh, M Alemozaffar, O Kucuk, B Carthon, CP Filson, MA Bilen, AB Jani	01/01/2019
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer	MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, VA Master, SS Ramalingam, TK Owonikoko, RD Harvey	01/01/2019
The addition of chemotherapy in the definitive management of high risk prostate cancer. Urologic oncology	MJ Ferris, Y Liu, J Ao, J Zhong, M Abugideiri, TW Gillespie, BC Carthon, MA Bilen, O Kucuk, AB Jani	11/01/2018
The Clinical Course of Patients With Prostate-Specific Antigen ≥100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening. Urology	AK Leung, L Hugar, D Patil, L Wong, B Carthon, KJ Carney, G Birdsong, KA Moses, VA Master	07/01/2018
Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clinical genitourinary cancer	MA Bilen, GMA Dutcher, Y Liu, D Ravindranathan, HT Kissick, BC Carthon, O Kucuk, WB Harris, VA Master	06/01/2018
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RZ Szmulewitz, CJ Peer, A Ibraheem, E Martinez, MF Kozloff, B Carthon, RD Harvey, P Fishkin, WP Yong, E Chiong, C Nabhan, T Karrison, WD Figg, WM Stadler, MJ Ratain	05/10/2018
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. Oncology	TK Owonikoko, AK Busari, S Kim, Z Chen, A Akintayo, C Lewis, BC Carthon, OB Alese, BF El-Rayes, SS Ramalingam, RD Harvey	01/01/2018
A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian journal of urology	RR Sekar, D Patil, Y Baum, J Pearl, A Bausum, MA Bilen, O Kucuk, WB Harris, BC Carthon, M Alemozaffar, CP Filson, JG Pattaras, PT Nieh, K Ogan, VA Master	10/01/2017
Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine	WB Harris, C Zhang, Y Liu, DK Robertson, MY Akbashev, BM Lingerfelt, O Kucuk, BC Carthon, TW Gillespie, AO Osunkoya, VA Master	06/01/2017
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone marrow transplantation	Z DeFilipp, CB Rosand, DA Goldstein, VA Master, BC Carthon, WB Harris, O Kucuk, Z Al-Kadhimi, JB Cohen, CR Flowers, MJ Lechowicz, AK Nooka, JL Kaufman, AA Langston, Z Chen, J Arora, EK Waller	01/01/2017
Clinical Considerations and Challenges in Treating Patients With Oligometastatic Prostate Cancer. Journal of oncology practice	BC Carthon	01/01/2017
The STAMPEDE trial: paradigm-changing data through innovative trial design. Translational cancer research	BC Carthon, ES Antonarakis	09/01/2016
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro-oncology	KR Patel, DH Lawson, RR Kudchadkar, BC Carthon, DE Oliver, D Okwan-Duodu, R Ahmed, MK Khan	10/01/2015
Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. The Canadian journal of urology	N Fatima, DJ Canter, BC Carthon, O Kucuk, VA Master, PT Nieh, K Ogan, AO Osunkoya	06/01/2015
Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model. Archives of biochemistry and biophysics	K Sahin, B Cross, N Sahin, K Ciccone, S Suleiman, AO Osunkoya, V Master, W Harris, B Carthon, R Mohammad, B Bilir, K Wertz, CS Moreno, CL Walker, O Kucuk	04/15/2015
Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association	W Hsiao, LA Herrel, C Yu, MW Kattan, DJ Canter, BC Carthon, K Ogan, VA Master	03/01/2015
Therapeutic options for a rising PSA after radical prostatectomy. The Canadian journal of urology	BC Carthon, DM Marcus, LA Herrel, AB Jani, PJ Rossi, DJ Canter	06/01/2013
Salvage therapy for locally recurrent prostate cancer after radiation. The Canadian journal of urology	DM Marcus, DJ Canter, AB Jani, RW Dobbs, DM Schuster, BC Carthon, PJ Rossi	12/01/2012

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.8	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	05/04/2024	Excellent
One star One star One star One star One star	04/28/2024	Dr. Carthon ( world class )
One star One star One star One star One star	03/24/2024	Dr Carthon is the consummate professioinal. He shows so much sincere interest in me and the quality of my life. He also communicates very clearly about my condition, mycurrent prognosis and what steps we may take later. Dr Carthon is the best there is.
One star One star One star One star One half star	02/25/2024	This last visit I got more clarification regarding my condition. I also asked better questions.
One star One star One star One star One star	02/25/2024	Dr. Carthone was excellent and very thorough.
One star One star One star One star One star	02/23/2024	Good experience
One star One star One star One star One star	02/12/2024	Excellent care -
One star One star One star One star One star	02/11/2024	Very good experience
One star One star One star One star One star	02/09/2024	Gooy
One star One star One star One star One star	01/11/2024	Excellent bedside manner. Very knowledgeable and professional. Would highly recommend him.
One star One star One star One star One star	12/31/2023	All was very good.
One star One star One star One star One star	12/09/2023	Dr Bradley Carthon was a breath of fresh air with someone being recently diagnosed with prostate cancer. He was very informative & very knowledgeable which eased a lot of my anxiety about my future. He informed us that he mostly dealt with patients needing chemotherapy. But he took his time to answer our questions & gave us references of urologist for moving forward. If Emory has half of their staff as Professional & knowledgeable as Dr.Carthon then all patients are in very GREAT hands!!
One star One star One star One star Empty star	12/08/2023	Good
One star One star One star One star One star	11/05/2023	Dr. Bradley Carthron was very attentive and receptive of our concerns and provided excellent advice and opinions.
One star One star One star One star One star	10/28/2023	Dr Carthon is a professional. I like doctoring with him.
One star One star One star One star One star	09/17/2023	Good
One star One star One star One star One star	08/25/2023	All of the providers gave me excellent care. I appreciated the visit with Dr. Carthon.
One star One star One star One star One star	08/19/2023	Excellent
One star One star One star One star One star	08/05/2023	Good
One star One star One star One star One star	07/27/2023	Dr Carthon was excellent and did a great job addressing our questions and needs!
One star One star One star One star One star	07/20/2023	Grateful for Dr. Carthon's care and expertise!
One star One star One star One star One star	07/13/2023	Dr Carthon is the best! So calm, professional, a wonderful teacher and caring physician!
One star One star One star One star One star	06/22/2023	Dr. Carthon is excellent! He is compassionate and knowledgeable. Has a very reassuring manner.
One star One star One star One star One star	04/20/2023	The good doctor is great! He takes his time with you and explains everything to you so you can understand. He is the best! A wonderful doctor
One star One star One star One star One star	02/18/2023	Good
One star One star One star One star One star	01/06/2023	All the people we saw (nurse, PA, and Dr) were all wonderful. They were all caring, easy to understand, and personable. Would highly recommend to anyone!
One star One star One star One star One star	12/29/2022	Excellent experience
One star One star One star One star One star	08/13/2022	Grateful for ongoing care and compassion
One star Empty star Empty star Empty star Empty star	07/25/2022	Doctor appeared to be angry with us as soon as he started talking. Began lecturing us as if we were imbeciles. Completely turned us off to him as an individual.
One star One star One star One star One star	06/02/2022	Very patient in listening to my concerns. Provided specific treatment options for my condition/diagnosis. lol